Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

Background Intravenous busulfan combined with therapeutic drug monitoring to guide
dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT). The …

Hematopoietic stem cell transplantation (HSCT) is a therapy used for multiple malignant and
nonmalignant diseases, with chemotherapy used for pretransplantation myeloablation. The …

Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …

PURPOSE It remains controversial whether busulfan-based versus total body irradiation
(TBI)–based regimens have comparable outcomes in patients with acute lymphoblastic …

Purpose Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan
(Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell …

ABSTRACT Introduction: Busulfan (Bu) is an alkylating agent with a limited therapeutic
margin and exhibits inter-patient variability in pharmacokinetics (PK). Despite decades of …

Abstract Background and Objectives: The wide variability in pharmacokinetics of busulfan in
children is one factor influencing outcomes such as toxicity and event-free survival. A meta …

Busulfan is a popular antileukemia chemotherapeutic alkylating agent widely known to
induce variety of serious adverse effects including chemobrain-related cognitive …